Idiopathic multicentric Castleman disease presenting progressive reticular honeycomb infiltration of lung and immunoglobulin G and immunoglobulin G4 dominant hypergammaglobulinemia: a case report
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Multicentric Castleman disease (MCD) is an uncommon systemic lymphoproliferative disorder that may cause multiple organ damage. Castleman disease-associated diffuse parenchymal lung disease (DPLD) has not been well studied. A 32-year-old man was referred to our hospital for progressive generalized weakness, light-headedness, and dyspnea on exertion for more than one year. Laboratory evaluations showed profound anemia, an elevated erythrocyte sedimentation rate, and an increased C-reactive protein level with polyclonal hypergammaglobulinemia. Chest radiography, computed tomography (CT), and positron emission tomography-CT scan demonstrated diffuse lung infiltration with multiple cystic lesions and multiple lymphadenopathy. In addition to these clinical laboratory findings, bone marrow, lung, and lymph node biopsies confirmed the diagnosis of idiopathic MCD (iMCD). Siltuximab, an interleukin-6 inhibitor, and glucocorticoid therapy were initiated. The patient has been tolerating the treatment well and had no disease progression or any complications in 4 years. Herein, we report this case of human herpesvirus-8-negative iMCD-associated DPLD accompanied by multiple cystic lesions, multiple lymphadenopathy, and polyclonal hypergammaglobulinemia with elevated immunoglobulin G (IgG) and IgG4 levels. We recommend a close evaluation of MCD in cases of DPLD with hypergammaglobulinemia.
Abstract
Multicentric Castleman disease (MCD) is an uncommon systemic lymphoproliferative disorder that may cause multiple organ damage. Castleman disease-associated diffuse parenchymal lung disease (DPLD) has not been well studied. A 32-year-old man was referred to our hospital for progressive generalized weakness, light-headedness, and dyspnea on exertion for more than one year. Laboratory evaluations showed profound anemia, an elevated erythrocyte sedimentation rate, and an increased C-reactive protein level with polyclonal hypergammaglobulinemia. Chest radiography, computed tomography (CT), and positron emission tomography-CT scan demonstrated diffuse lung infiltration with multiple cystic lesions and multiple lymphadenopathy. In addition to these clinical laboratory findings, bone marrow, lung, and lymph node biopsies confirmed the diagnosis of idiopathic MCD (iMCD). Siltuximab, an interleukin-6 inhibitor, and glucocorticoid therapy were initiated. The patient has been tolerating the treatment well and had no disease progression or any complications in 4 years. Herein, we report this case of human herpesvirus-8-negative iMCD-associated DPLD accompanied by multiple cystic lesions, multiple lymphadenopathy, and polyclonal hypergammaglobulinemia with elevated immunoglobulin G (IgG) and IgG4 levels. We recommend a close evaluation of MCD in cases of DPLD with hypergammaglobulinemia.
참고문헌 (20)
- Castleman B, "Localized mediastinal lymphnode hyperplasia resembling thymoma", Cancer, 9, pp.822~830 (1956)
- Fajgenbaum DC, "Castleman disease pathogenesis", Hematol Oncol Clin North Am, 32, pp.11~21 (2018)
- Shahidi H, "Castleman’s disease", Mayo Clin Proc, 70, pp.969~977 (1995)
- Takenaka K, "A case of IgG4-related disease with features of Mikulicz’s disease, and retroperitoneal fibrosis and lymphadenopathy mimicking Castleman’s disease", Mod Rheumatol, 21, pp.410~414 (2011)
- Huang H, "Castleman disease-associated diffuse parenchymal lung disease: A STROBE-compliant retrospective observational analysis of 22 cases in a tertiary Chinese hospital", Medicine(Baltimore), 96, pp.e8173~ (2017)
- Fajgenbaum DC, "International, evidence-based consensus diagnostic criteria for HHV-8-negative", idiopathic multicentric Castleman disease, 2017, pp.129, 1646~1657
- Wallace ZS, "The 2019 American College of Rheumatology", European League Against Rheumatism classification criteria for IgG4-related disease, 2020, pp.72, 7~19
- Oksenhendler E, "The full spectrum of Castleman disease : 273 patients studied over 20 years", Br J Haematol, 180, pp.206~216 (2018)
- Bowne WB, "The management of unicentric and multicentric Castleman’s disease : a report of 16 cases and a review of the literature", Cancer, 85, pp.706~717 (1999)
- Palestro G, "Castleman’s disease", Adv Clin Path, 3, pp.11~22 (1999)
- Vassallo R, "Pulmonary Langerhans’-cell histiocytosis", N Engl J Med, 342, pp.1969~1978 (2000)
- Inoue D, "Immunoglobulin G4-related lung disease : CT findings with pathologic correlations", Radiology, 251, pp.260~270 (2009)
- Mochizuki H, "Overlap of IgG4-related disease and multicentric Castleman’s disease in a patient with skin lesions", Intern Med, 56, pp.1095~1099 (2017)
- Sato Y, "Systemic IgG4-related lymphadenopathy : a clinical and pathologic comparison to multicentric Castleman’s disease", Mod Pathol, 22, pp.589~599 (2009)
- van Rhee F, "International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease", Blood, 132, pp.2115~2124 (2018)
- Kamisawa T, "A new clinicopathological entity of IgG4-related autoimmune disease", J Gastroenterol, 38, pp.982~984 (2003)
- Yamashita K, "Lung involvement in IgG4-related lymphoplasmacytic vasculitis and interstitial fibrosis : report of 3 cases and review of the literature", Am J Surg Pathol, 32, pp.1620~1626 (2008)
- Liu AY, "Idiopathic multicentric Castleman’s disease : a systematic literature review", Lancet Haematol, 3, pp.e163~e175 (2016)
- van Rhee F, "Treatment of idiopathic Castleman disease", Hematol Oncol Clin North Am, 32, pp.89~106 (2018)
- van Rhee F, "A phase 2, open-label, multicenter study of the long-term safety of siltuximab(an anti-interleukin-6 monoclonal antibody)in patients with multicentric Castleman disease", Oncotarget, 6, pp.30408~30419 (2015)